Document:

EX-10.1

 Exhibit 10.1 

SECURITIES PURCHASE AGREEMENT 

This Securities Purchase Agreement (this “Agreement”) is made and entered into as of September 10th, 2014, by and between International Stem Cell Corporation, a Delaware corporation (the “Company”), and the investors listed on the signature page hereof (individually a
“Purchaser” and collectively, the “Purchasers”). 
 RECITALS 

WHEREAS, the Company desires to sell to the Purchasers, and the Purchasers desire to purchase from the Company, on the terms and conditions
set forth in this Agreement, 4,444,445 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”); 

WHEREAS, the Purchasers are executive officers and directors of the Company; 

WHEREAS, each Purchaser is knowledgeable about (i) the Company’s business, financial condition, results of operations, prospects and
risks, (ii) any recent developments related thereto, and (iii) the filings made by the Company with the Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and the information contained therein. 
 NOW, THEREFORE, in consideration of the foregoing, the
mutual promises hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. AGREEMENT TO PURCHASE AND SELL SECURITIES. 

(a) Subject to the terms and conditions of this Agreement, the Company shall sell to the Purchasers the respective number of Shares set forth
on the signature page hereof. The purchase price of each Share shall be $0.09. 
 2. CLOSING.  

(a) The purchase and sale of the Shares shall take place at the Company’s principal executive offices, 5950 Priestly Drive, Carlsbad,
California 92008, upon execution of this Agreement (which time and place are referred to in this Agreement as the “Closing”). 

(b) At the Closing, against delivery of full payment for the Shares sold hereunder by check payable to the Company or by wire transfer of
immediately available funds in accordance with the Company’s instructions, the Company shall (i) issue and deliver or cause to be delivered to each Purchaser one or more stock certificates registered in the name of Purchaser or
(ii) arrange for the book-entry transfer of the Shares, all of which Shares shall bear the legend set forth in Section 4(e) below; provided, however, that in lieu of delivery of the Shares at the Closing, the Company may
furnish to the Purchasers a copy of the irrevocable instructions to the Company’s transfer agent instructing the transfer agent to deliver a certificate or certificates evidencing, or arrange for the book-entry transfer of, the Shares,
registered in the name of the Purchasers. 

  
 1 

 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby represents and
warrants to each Purchaser that: 
 (a) Due Authorization. All corporate actions on the part of the Company necessary for the
authorization, execution, delivery of, and the performance of all obligations of the Company under this Agreement, including the authorization, issuance, and delivery of the Shares, have been taken and no further consent or authorization of the
Company, the Board of Directors of the Company or the Company’s stockholders is required. This Agreement constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as
may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, and (ii) the effect of rules of law governing the
availability of equitable remedies. 
 (b) Valid Issuance of the Shares. When issued at the Closing, the Shares will be, duly
authorized, validly issued, fully paid and non-assessable, free and clear from all taxes and liens, claims and encumbrances imposed by the Company, other than restrictions under applicable securities laws, and will not be subject to any preemptive
rights or similar rights that have not been waived by the holders thereof. 
 (c) Exchange Act Documents. The Company has filed all
reports, schedules, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Exchange Act and the rules and regulations promulgated thereunder (the “Exchange Act
Documents”). Each of the Exchange Act Documents, as of the respective dates thereof (or, if amended or superseded by a filing or submission, as the case may be, prior to the Closing, then on the date of such filing or submission, as the
case may be), (1) did not contain any untrue statement of a material fact nor omit to state a material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading and
(2) complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to such Exchange Act Document. 

4. REPRESENTATIONS AND WARRANTIES OF EACH PURCHASER. Each Purchaser, separately and not jointly hereby represents and warrants
to the Company that: 
 (a) Due Authorization. All action on the part of the Purchaser necessary for the authorization, execution,
delivery of and the performance of the transactions contemplated by this Agreement have been taken and no further consent or authorization of the Purchaser is necessary. This Agreement, when delivered by the Purchaser in accordance with the terms
hereof, will constitute Purchaser’s legal, valid and binding obligation, enforceable in accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application
relating to or affecting the enforcement of creditors’ rights generally and (ii) the effect of rules of law governing the availability of equitable remedies. 

(b) Purchase for Own Account. The Securities are being acquired for investment for the Purchaser’s own account, not as a nominee
or agent, in the ordinary course of business, and not with a view to the public resale or distribution thereof within the meaning of the Securities Act of 1933, as amended. The Purchaser does not have any agreement or understanding, direct or
indirect, with any other person to sell or otherwise distribute the Securities. Notwithstanding the foregoing, the parties hereto acknowledge the Purchaser’s right at all times to sell or otherwise dispose of all or any part of the Securities
in compliance with applicable federal and state securities laws and as otherwise contemplated by this Agreement. 
 (c) Investment
Experience and Knowledge of the Company. The Purchaser understands that the purchase of the Securities involves substantial risk. The Purchaser has experience as an investor in securities of the Company and companies similar to the Company and
acknowledges that he can bear the economic risk of his investment in the Shares and has such knowledge and experience in 

  
 2 

 
financial or business matters that he is capable of evaluating the merits and risks of this investment in the Shares and protecting his own interests in connection with this investment. The
Purchaser is fully informed of the Company’s business, financial condition, results of operation, prospects and risks. 
 (d)
Restricted Securities and Restrictions on Transfer. 
         (i) The
Purchaser understands that the Securities have not been registered under the Securities Act and the Purchaser agrees that he will not sell, offer to sell, assign, pledge, hypothecate or otherwise transfer any of the Securities (except as permitted
in Section 4(d)(iii) below) unless (1) pursuant to an effective registration statement under the Securities Act, (2) the Purchaser provides a reasonably acceptable legal opinion to the Company, to the effect that a sale,
assignment, pledge, hypothecation or other transfer of the Securities may be made without registration under the Securities Act, (3) the Purchaser provides the Company a “no action” letter from the SEC to the effect that the transfer
of the Securities without registration will not result in a recommendation by the Staff of the SEC that enforcement action be taken with respect thereto, (4) the Purchaser provides the Company with reasonable assurances (in the form of seller
and broker representation letters) that the Securities can be sold pursuant to Rule 144 promulgated under the Securities Act (“Rule 144”), or (5) pursuant to any other exception contained in the Securities Act provided
that the Purchaser provides a reasonably acceptable legal opinion to the Company. 

        (ii) Prior to any proposed transfer pursuant to clause (2), (3), (4) or
(5) in Section 4(d)(i) above, the Purchaser shall give written notice to the Company of such Purchaser’s intention to effect such transfer. Each such notice shall describe the manner and circumstances of the proposed transfer
in sufficient detail, and shall be accompanied by the applicable legal opinion, “no action” letter or seller and broker representation letters. 

        (iii) Notwithstanding the foregoing provisions of this
Section 4(d), no registration statement, legal opinion or “no action” letter shall be necessary for a transfer of the Shares by gift, will or intestate succession to the Purchaser’s spouse or other immediate family
members. 
 (e) Legends. Purchaser agrees that, to the extent necessary, the certificates representing the Shares, the Warrant and
the Warrant Shares shall bear substantially the following legends: 
         (i)
“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN
THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
(2) AN OPINION OF HOLDER’S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.” 

        (ii) Any other legend required to be placed thereon by applicable state or
federal laws. 

  
 3 

 5. MISCELLANEOUS. 

(a) Successors and Assigns. The terms and conditions of this Agreement will inure to the benefit of and be binding upon the respective
successors and permitted assigns of the parties. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Purchasers. Each Purchaser may assign its rights under this Agreement to any
person to whom such Purchaser assigns or transfers any of the Shares, provided that such transferee agrees in writing to be bound by the terms and provisions of this Agreement, and such transfer is in compliance with the terms and provisions of this
Agreement and permitted by federal and state securities laws. 
 (b) Governing Law. This Agreement will be governed by and construed
and enforced under the internal laws of the State of Delaware, without reference to principles of conflict of laws or choice of laws. 
 (c)
Survival. The representations and warranties of the Company contained in Section 3 of this Agreement and of the Purchaser contained in Section 4 of this Agreement shall survive the Closing. 

(d) Counterparts. This Agreement may be executed counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. 
 (e) Headings. The headings and captions used in this Agreement are used for convenience
only and are not to be considered in construing or interpreting this Agreement. 
 (f) Notices. Any notices and other communications
required or permitted under this Agreement shall be in writing and shall be delivered (i) personally by hand or by courier, (ii) mailed by United States first-class mail, postage prepaid or (iii) sent by facsimile or other electronic
transmission directed to the address or facsimile number or other address for electronic transmission set forth below. All such notices and other communications shall be deemed given upon (i) receipt or refusal of receipt, if delivered
personally, (ii) three (3) days after being placed in the mail, if mailed, or (iii) confirmation of facsimile transfer or other electronic transmission, if faxed. 

If to the Company: 

International Stem Cell Corporation. 

5950 Priestly Drive, Carlsbad, California 92008 

Tel: (760) 940-6383 
 Fax:
(760) 476-0600 
 Attention: Chief Financial Officer 

with a copy to: 
 DLA Piper LLP
(US) 
 4365 Executive Drive, Suite 1100 

San Diego, California 92121 

Tel: (858) 677-1400 
 Fax:
(858) 638-5043 
 Attention: Douglas Rein 

If to a Purchaser: 
 5950
Priestly Drive, Carlsbad, California 92008 
 Attn: Dr. R. Semechkin 

  
 4 

 With a copy to: 

McLane, Graf, Raulerson & Middleton, Professional Association 

City Hall Plaza – 900 Elm Street 

P.O. Box 326 
 Manchester, New
Hampshire 03105-0326 
 Attn. Michael B. Tule, Esq. 

Tel. (603) 628-1290 
 Fax:
(603) 625 5650 
 (g) Amendments and Waivers. This Agreement may be amended and the observance of any term of this Agreement may
be waived only with the written consent of the Company and the Purchasers. Any amendment effected in accordance with this Section 5(g) will be binding upon all Purchasers, the Company and their respective successors and assigns. 

(h) Severability. If any provision of this Agreement is held to be unenforceable under applicable law, such provision will be excluded
from this Agreement and the balance of the Agreement will be interpreted as if such provision were so excluded and will be enforceable in accordance with its terms. 

(i) Entire Agreement. This Agreement, together with all exhibits and schedules thereto, constitutes the entire agreement and
understanding of the parties with respect to the subject matter hereof and thereof and supersede any and all prior negotiations, correspondence, agreements, understandings, duties or obligations between the parties with respect to the subject matter
hereof and thereof. 
 (j) Fees, Costs and Expenses. All fees, costs and expenses (including attorneys’ fees and expenses)
incurred by any party hereto in connection with the preparation, negotiation and execution of this Agreement and the exhibits and schedules thereto and the consummation of the transactions contemplated hereby and thereby (including the costs
associated with any filings with, or compliance with any of the requirements of any governmental authorities), shall be the sole and exclusive responsibility of such party. 

(k) Waivers. No waiver by any party to this Agreement of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of
any such right accruing to it thereafter. 

  
 5 

 (l) Remedies. In addition to being entitled to exercise all rights provided herein or
granted by law, including recovery of damages, the Purchasers and the Company will be entitled to specific performance under this Agreement. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of
any breach of obligations described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date and year first above written. 

INTERNATIONAL STEM CELL CORPORATION 

			
		
	By:	 	     /s/ Jay Novak

		 	Name: Jay Novak
		 	Title: Chief Financial Officer

  

			
	PURCHASERS:	 	
		
	Andrey Semechkin	 	3,888,889 shares

  

			
	By:	 	     /s/ Andrey Semechkin

	Andrey Semechkin
	c/o International Stem Cell Corporation
	5950 Priestly Drive, Carlsbad, California 92008
	Tel: (760) 940-6383
	Fax: (760) 476-0600

  

			
	Ruslan Semechkin	 	555,556 shares

  

			
	
	By:	 	     /s/ Ruslan Semechkin

	Ruslan Semechkin
	c/o International Stem Cell Corporation
	5950 Priestly Drive, Carlsbad, California 92008
	Tel: (760) 940-6383
	Fax: (760) 476-0600

  
 6Exhibit 10.1 

 

BOARD OF DIRECTORS AGREEMENT

 

This Board of Directors Agreement (“Agreement”)
made as of September 11, 2014 by and between Apollo Medical Holdings, Inc., with its principal place of business at 700 N. Brand
Blvd, Suite 2200, Glendale, California, 91203 (“ApolloMed”) and Warren Hosseinion, M.D., with an address of [ ], (the
“Director”) provides for director services, according to the following terms and conditions:

 

I.      Services Provided

 

ApolloMed agrees to engage the Director to serve on the Board
of Directors of ApolloMed and to provide those services required of a director under ApolloMed’s Certificate of Incorporation
and Bylaws, as both may be amended from time, to time (“Articles and Bylaws”) and under the General Corporation Law
of Delaware, the federal securities laws and other state and federal laws and regulations, as applicable.

 

II.      Nature of Relationship

 

The Director is an independent contractor and will not be deemed
an employee of ApolloMed for purposes of employee benefits, income tax withholding, F.I.C.A. taxes, unemployment benefits or otherwise. 
The Director shall not enter into any agreement or incur any obligations on ApolloMed’s behalf.

 

ApolloMed will supply, at no cost to the Director:  periodic
briefings on the business, director packages for each board and committee meeting, copies of minutes of meetings and any other
materials that are required under ApolloMed’s Articles and Bylaws or the charter of any committee of the board on which the
Director serves and any other materials which may, by mutual agreement, be necessary for performing the services requested under
this Agreement.

 

III.      Director’s Warranties

 

The Director warrants that no other party has exclusive rights
to his services in the specific areas in which ApolloMed is conducting business and that the Director is in no way compromising
any rights or trust between any other party and the Director or creating a conflict of interest as a result of his participation
on the Board of Directors of ApolloMed.  The Director also warrants and covenants that so long as the Director serves on the
Board of Directors of ApolloMed, the Director will not enter into another agreement that will create a conflict of interest with
this Agreement.  The Director further warrants and covenants that he will comply with all applicable state and federal laws
and regulations, as applicable, including Sections 10 and 16 of the Securities and Exchange Act of 1934.

 

Throughout the term of this Agreement, the Director agrees he
will not, without obtaining ApolloMed’s prior written consent, directly or indirectly engage or prepare to engage in any
activity in competition with any ApolloMed business or product, including products in the development, accept employment or provide
services to (including service as a member of a board of directors), or establish a business in competition with ApolloMed.

 

IV.      Expenses

 

ApolloMed will reimburse the Director for reasonable expenses
approved in advance (other than the cost of airfare and hotel accomodations), such approval not to be unreasonably withheld. 
Invoices for expenses, with receipts attached, shall be submitted. Such invoices must be approved by ApolloMed’s Chief Executive
Officer as to form and completeness.

 

    	1

    	 

    

 

V.      Indemnification and Insurance

 

ApolloMed will execute an indemnification agreement in favor
of the Director substantially in the form of the agreement attached hereto as Exhibit B (the “Indemnification Agreement”). 
In addition, so long as ApolloMed’s indemnification obligations exist under the Indemnification Agreement, ApolloMed shall
provide the Director with directors’ and officers’ liability insurance coverage in the amounts specified in the Indemnification
Agreement.

 

VI.      Term of Agreement

 

This Agreement shall be in effect from the date hereof through
the last date of the Director’s current term as a member of ApolloMed’s Board of Directors.  This Agreement shall
be automatically renewed on the date of the Director’s reelection as a member of ApolloMed’s Board of Director’s
for the period of such new term unless the Board of Directors determines not to renew this Agreement.   Any amendment
to this Agreement must be approved by a written action of ApolloMed’s Board of Directors.  Amendments to Section IV
Expenses hereof do not require the Director’s consent to be effective.

 

VII.      Termination

 

This Agreement shall automatically terminate upon the death
of the Director or upon his resignation or removal from, or failure to win election or reelection to, the ApolloMed Board of Directors.

 

In the event of any termination of this Agreement, the Director
agrees to return or destroy any materials transferred to the Director under this Agreement except as may be necessary to fulfill
any outstanding obligations hereunder.  The Director agrees that ApolloMed has the right of injunctive relief to enforce this
provision.

 

ApolloMed’s and the Director’s continuing obligations
hereunder in the event of such termination shall be subject to the terms of Section XIV hereof.

 

VIII.      Limitation of Liability

 

Under no circumstances shall ApolloMed be liable to the Director
for any consequential damages claimed by any other party as a result of representations made by the Director with respect to ApolloMed
which are materially different from any to those made in writing by ApolloMed.

 

Furthermore, except for the maintenance of confidentiality,
neither party shall be liable to the other for delay in any performance, or for failure to render any performance under this Agreement
when such delay or failure is caused by Government regulations (whether or not valid), fire, strike, differences with workmen,
illness of employees, flood, accident, or any other cause or causes beyond reasonable control of such delinquent party.

 

IX.      Confidentiality

 

The Director agrees to sign and abide by ApolloMed’s Director
Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A.

 

X.      Resolution of Dispute

 

Any dispute regarding this Agreement (including without limitation
its validity, interpretation, performance, enforcement, termination and damages) shall be determined in accordance with the laws
of the State of California, the United States of America.  Any action under this paragraph shall not preclude any party hereto
from seeking injunctive or other legal relief to which each party may be entitled.

 

    	2

    	 

    

 

XI.      Sole Agreement

 

This Agreement (including agreements executed in substantially
in the form of the exhibits attached hereto) supersedes all prior or contemporaneous written or oral understandings or agreements,
and may not be added to, modified, or waived, in whole or in part, except by a writing signed by the party against whom such addition,
modification or waiver is sought to be asserted.

 

XII.      Assignment

 

This Agreement and all of the provisions hereof shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns and, except as otherwise
expressly provided herein, neither this Agreement, nor any of the rights, interests or obligations hereunder shall be assigned
by either of the parties hereto without the prior written consent of the other party.

 

XIII.      Notices

 

Any and all notices, requests and other communications required
or permitted hereunder shall be in writing, registered mail or by facsimile, to each of the parties at the addresses set forth
above or the numbers set forth below:

 

	The Director:	Warren Hosseinion, M.D.
	 	[  ]
	 	 
	 	 
	ApolloMed:	Apollo Medical Holdings, Inc.
	 	700 N. Brand Blvd, Suite 220
	 	Glendale, CA  91203

 

 

Any such notice shall be deemed given when received and notice
given by registered mail shall be considered to have been given on the tenth (10th) day after having been sent in the manner provided
for above.

 

XIV.      Survival of Obligations

 

Notwithstanding the expiration or termination of this Agreement,
neither party hereto shall be released hereunder from any liability or obligation to the other which has already accrued as of
the time of such expiration or termination (including, without limitation, ApolloMed’s obligation to make any fees and expense
payments required pursuant to Section IV and/or ApolloMed’s indemnification and insurance obligations set forth in Section
V hereof) or which thereafter might accrue in respect of any act or omission of such party prior to such expiration or termination.

 

XV.      Attorneys’ Fees

 

If any legal action or other proceeding
is brought for the enforcement of this Agreement, or because of a dispute, breach or default in connection with any of the provisions
hereof, the successful or prevailing party (including a party successful or prevailing in defense) shall be entitled to recover
its actual attorneys’ fees and other costs incurred in that action or proceeding, in addition to any other relief to which
it may be entitled.

  

    	3

    	 

    

 

XVI.      Severability

 

Any provision of this Agreement which is determined to be invalid
or unenforceable shall not affect the remainder of this Agreement, which shall remain in effect as though the invalid or unenforceable
provision had not been included herein, unless the removal of the invalid or unenforceable provision would substantially defeat
the intent, purpose or spirit of this Agreement.

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed as of the date first written above.

Director:Apollo Medical Holdings, Inc.

  

	Director:	 	Apollo Medical Holdings, Inc.
	 	 	 	 
	 	 	 	 
	Signature:	 /s/ Warren Hosseinion	By: 	 /s/ Mitchell Creem
	 	Warren Hosseinion, M.D.	 	Mitchell Creem, Chief Financial Officer

 

    	4

    	 

    

 

EXHIBIT A

 

PROPRIETARY INFORMATION AGREEMENT

 

THIS BOARD OF DIRECTORS’ PROPRIETARY INFORMATION AGREEMENT
(“Agreement”) is made and entered into this 11th day of September, 2014 by and between APOLLO MEDICAL HOLDINGS,
INC., a Delaware corporation (“ApolloMed”), and Warren Hosseinion, M.D. (the “Director”).

 

RECITALS

 

WHEREAS, the Director has been elected to serve on the Board
of Directors of ApolloMed;

 

WHEREAS, the parties desire to assure the confidential status
of the information which may be disclosed by ApolloMed to the Director in connection with the Director serving on ApolloMed’s
Board of Directors;

 

NOW THEREFORE, in reliance upon and in consideration
of the following undertaking, the parties agree as follows:

 

AGREEMENT

 

      1.      
Subject to the limitations set forth in Paragraph 2, all information disclosed by ApolloMed to the Director shall be deemed to
be "Proprietary Information".  In particular, Proprietary Information shall be deemed to include any information,
process, technique, algorithm, program, design, drawing, formula or test data relating to any research project, work in process,
future development, engineering, manufacturing, marketing, servicing, financing or personnel matter relating to ApolloMed, its
present or future products, sales, suppliers, customers, employees, investors, or business, whether or oral, written, graphic or
electronic form.

 

      2.      
The term "Proprietary Information" shall not be deemed to include the following information: (i) information which is
now, or hereafter becomes, through no breach of this Agreement on the part of the Director, generally known or available to the
public; (ii) is known by the Director at the time of receiving such information; (iii) is hereafter furnished to the Director by
a third party, as a matter of right and without restriction on disclosure; or (iv) is the subject of a written permission to disclose
provided by ApolloMed.

 

      3.      
The Director shall maintain in trust and confidence and not disclose to any third party or use for any unauthorized purpose any
Proprietary Information received from ApolloMed.  The Director may use such Proprietary Information only to the extent required
to accomplish the purposes of his position as a Director of ApolloMed.  The Director shall not use Proprietary Information
for any purpose or in any manner which would constitute a violation of any laws or regulations, including without limitation the
export control laws of the United States.  No other rights of licenses to trademarks, inventions, copyrights, or patents are
implied or granted under this Agreement.

 

      4.      
Proprietary Information supplied shall not be reproduced in any form except as required to accomplish the intent of this Agreement.

 

      5.      
The Director represents, warrants and covenants that he shall protect the Proprietary Information received with at least the same
degree of care used to protect his own Proprietary Information from unauthorized use or disclosure. 

 

      6.      
All Proprietary Information (including all copies thereof) shall remain in the property of ApolloMed, and shall be returned to
ApolloMed (or destroyed) after the Director's need for it has expired, or upon request of ApolloMed, and in any event, upon the
termination of that certain Board of Directors Agreement, of even date herewith, between ApolloMed and the Director (the “Director
Agreement”).

 

    	5

    	 

    

 

      7.      
Notwithstanding any other provision of this Agreement, disclosure of Proprietary Information shall not be precluded if such disclosure:

 

(a)   is in response to a valid order of a court or
other governmental body of the United States or any political subdivision thereof; provided, however, that the Director shall first
have given ApolloMed notice of the Director’s receipt of such order and ApolloMed shall have had an opportunity to obtain
a protective order requiring that the Proprietary Information so disclosed be used only for the purpose for which the order was
issued;

 

(b)   is otherwise required by law; or

 

(c)   is otherwise necessary to establish rights or
enforce obligations under this Agreement, but only to the extent that any such disclosure is necessary.

 

      8.      
This Agreement shall continue in full force and effect during the term of the Director Agreement. This Agreement may be terminated
at any time thereafter upon thirty (30) days written notice to the other party.  The termination of this Agreement shall not
relieve the Director of the obligations imposed by Paragraphs 3, 4, 5 and 11 of this Agreement with respect to Proprietary information
disclosed prior to the effective date of such termination and the provisions of these Paragraphs shall survive the termination
of this Agreement for a period of eighteen (18) months from the date of such termination.

 

      9.    
This Agreement shall be governed by the laws of the State of California as those laws are applied to contracts entered into and
to be performed entirely in California by California residents.

 

      10.     
This Agreement contains the final, complete and exclusive agreement of the parties relative to the subject matter hereof and may
not be changed, modified, amended or supplemented except by a written instrument signed by both parties.

 

      11.     
Each party hereby acknowledges and agrees that in the event of any breach of this Agreement by the Director, including, without
limitation, an actual or threatened disclosure of Proprietary Information without the prior express written consent of ApolloMed,
ApolloMed will suffer an irreparable injury, such that no remedy at law will afford it adequate protection against, or appropriate
compensation for, such injury.  Accordingly, each party hereby agrees that ApolloMed shall be entitled to specific performance
of the Director's obligations under this Agreement, as well as such further injunctive relief as may be granted by a court of competent
jurisdiction.

  

	Director:	Apollo Medical Holdings, Inc.
	 	 
	Signature:  /s/ Warren Hosseinion	Signature:  /s/ Mitchell R. Creem
	 	 
	Print Name:  Warren Hosseinion	Print Name:  Mitchell R. Creem 
	 	 
	 	Title:  Chief Financial Officer

 

    	6

    	 

    

 

EXHIBIT B

 

INDEMNIFICATION AGREEMENT

 

    	7

    	 

    

 

INDEMNIFICATION AGREEMENT

 

INDEMNIFICATION AGREEMENT
(this “Agreement”) dated as of September 11, 2014 by and among APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation
(the “Company”) and Warren Hosseinion, M.D. ( “Indemnitee”).

 

R E C I T A L S

 

A. The Company and
Indemnitee recognize the continued difficulty in obtaining liability insurance for its directors, officers, employees, stockholders,
controlling persons, agents and fiduciaries, the significant increases in the cost of such insurance and the general reductions
in the coverage of such insurance.

 

B. The Company
and Indemnitee further recognize the substantial increase in corporate litigation in general, which subjects directors, officers,
employees, controlling persons, stockholders, agents and fiduciaries to expensive litigation risks at the same time as the availability
and coverage of liability insurance has been severely limited.

 

C. Indemnitee does
not regard the current protection available as adequate under the present circumstances, and Indemnitee and other directors, officers,
employees, stockholders, controlling persons, agents and fiduciaries of the Company may not be willing to serve in such capacities
without additional protection.

 

D. The Company (i)
desires to attract and retain highly qualified individuals and entities, such as Indemnitee, to serve the Company and, in part,
in order to induce Indemnitee to be involved with the Company and (ii) wishes to provide for the indemnification and advancing
of expenses to Indemnitee to the maximum extent permitted by law.

 

E.  In view of the
considerations set forth above, the Company desires that Indemnitee be indemnified by the Company as set forth herein.

 

NOW, THEREFORE, the
Company and Indemnitee hereby agree as follows:

 

1.Indemnification

 

    	1

    	 

    

 

a.Indemnification
of Expenses. The Company shall indemnify and hold harmless Indemnitee (including its respective directors, officers, partners,
former partners, members, former members, employees, agents and spouse, as applicable) and each person who controls any of them
or who may be liable within the meaning of Section 15 of the Securities Act of 1933, as amended (the “Securities Act”),
or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the fullest extent permitted
by law if Indemnitee was or is or becomes a party to or witness or other participant in, or is threatened to be made a party to
or witness or other participant in, any threatened, pending or completed action, suit, proceeding or alternative dispute resolution
mechanism, or any hearing, inquiry or investigation that Indemnitee believes might lead to the institution of any such action,
suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal, administrative, investigative or other (hereinafter
a “Claim”) by reason of (or arising in part or in whole out of) any event or occurrence related to the fact that Indemnitee
is or was or may be deemed a director, officer, stockholder, employee, controlling person, agent or fiduciary of the Company, or
any subsidiary of the Company, or is or was or may be deemed to be serving at the request of the Company as a director, officer,
stockholder, employee, controlling person, agent or fiduciary of another corporation, partnership, limited liability company, joint
venture, trust or other enterprise, or by reason of any action or inaction on the part of Indemnitee while serving in such capacity
including, without limitation, any and all losses, claims, damages, expenses and liabilities, joint or several (including any investigation,
legal and other expenses incurred in connection with, and any amount paid in settlement of, any action, suit, proceeding or any
claim asserted) under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law
or otherwise or which relate directly or indirectly to the registration, purchase, sale or ownership of any securities of the Company
or to any fiduciary obligation owed with respect thereto or as a direct or indirect result of any Claim made by any stockholder
of the Company against Indemnitee and arising out of or related to any round of financing of the Company (including but not limited
to Claims regarding non-participation, or non-pro rata participation, in such round by such stockholder), or made by a third party
against Indemnitee based on any misstatement or omission of a material fact by the Company in violation of any duty of disclosure
imposed on the Company by federal or state securities or common laws (hereinafter an “Indemnification Event”) against
any and all expenses (including attorneys’ fees and all other costs, expenses and obligations incurred in connection with
investigating, defending a witness in or participating in (including on appeal), or preparing to defend, be a witness in or participate
in, any such action, suit, proceeding, alternative dispute resolution mechanism, hearing, inquiry or investigation), judgments,
fines, penalties and amounts paid in settlement (if, and only if, such settlement is approved in advance by the Company, which
approval shall not be unreasonably withheld) of such Claim and any federal, state, local or foreign taxes imposed on Indemnitee
as a result of the actual or deemed receipt of any payments under this Agreement (collectively, hereinafter “Expenses”),
including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses. Such payment
of Expenses shall be made by the Company as soon as practicable but in any event no later than ten (10) days after written demand
by Indemnitee therefor is presented to the Company.

 

b.Reviewing Party.
Notwithstanding the foregoing, (i) the obligations of the Company under Section 1(a) shall be subject to the condition that the
Reviewing Party (as described in Section 10(e) hereof) shall not have determined (in a written opinion, in any case in which the
Independent Legal Counsel referred to in Section 1(e) hereof is involved) that Indemnitee would not be permitted to be indemnified
under applicable law, and (ii) Indemnitee acknowledges and agrees that the obligation of the Company to make an advance payment
of Expenses to Indemnitee pursuant to Section 2(a) (an “Expense Advance”) shall be subject to the condition that, if,
when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so indemnified under applicable
law, the Company shall be entitled to be reimbursed by Indemnitee (who hereby agrees to reimburse the Company) for all such amounts
theretofore paid; provided, however, that if Indemnitee has commenced or thereafter commences legal proceedings in a court of competent
jurisdiction to secure a determination that Indemnitee should be indemnified under applicable law, any determination made by the
Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law shall not be binding and Indemnitee
shall not be required to reimburse the Company for any Expense Advance until a final judicial determination is made with respect
thereto (as to which all rights of appeal therefrom have been exhausted or lapsed). Indemnitee’s obligation to reimburse
the Company for any Expense Advance shall be unsecured and no interest shall be charged thereon. If there has not been a Change
in Control (as defined in Section 10(c) hereof), the Reviewing Party shall be selected by the Board of Directors, and if there
has been such a Change in Control (other than a Change in Control which has been approved by a majority of the Company’s
Board of Directors who were directors immediately prior to such Change in Control), the Reviewing Party shall be the Independent
Legal Counsel referred to in Section 1(e) hereof. If there has been no determination by the Reviewing Party or if the Reviewing
Party determines that Indemnitee substantively would not be permitted to be indemnified in whole or in part under applicable law,
Indemnitee shall have the right to commence litigation seeking an initial determination by the court or challenging any such determination
by the Reviewing Party or any aspect thereof, including the legal or factual bases therefor, and the Company hereby consents to
service of process and to appear in any such proceeding. Any determination by the Reviewing Party otherwise shall be conclusive
and binding on the Company and Indemnitee.

 

    	2

    	 

    

 

c.Contribution.
If the indemnification provided for in Section 1(a) above for any reason is held by a court of competent jurisdiction to be unavailable
to Indemnitee in respect of any losses, claims, damages, expenses or liabilities referred to therein, then the Company, in lieu
of indemnifying Indemnitee thereunder, shall contribute to the amount paid or payable by Indemnitee as a result of such losses,
claims, damages, expenses or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by
the Company and Indemnitee, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault
of the Company and Indemnitee in connection with the action or inaction which resulted in such losses, claims, damages, expenses
or liabilities, as well as any other relevant equitable considerations. In connection with the registration of the Company’s
securities, the relative benefits received by the Company and Indemnitee shall be deemed to be in the same respective proportions
that the net proceeds from the offering (before deducting expenses) received by the Company and Indemnitee, in each case as set
forth in the table on the cover page of the applicable prospectus, bear to the aggregate public offering price of the securities
so offered. The relative fault of the Company and Indemnitee shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information
supplied by the Company or Indemnitee and the parties’ relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.

 

The Company and Indemnitee
agree that it would not be just and equitable if contribution pursuant to this Section 1(c) were determined by pro rata or per
capita allocation or by any other method of allocation which does not take account of the equitable considerations referred to
in the immediately preceding paragraph. In connection with the registration of the Company’s securities, in no event shall
Indemnitee be required to contribute any amount under this Section 1(c) in excess of the lesser of (i) that proportion of the total
of such losses, claims, damages or liabilities indemnified against equal to the proportion of the total securities sold under such
registration statement which is being sold by Indemnitee or (ii) the proceeds received by Indemnitee from its sale of securities
under such registration statement. No person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the Securities Act) shall be entitled to contribution from any person who was not found guilty of such fraudulent misrepresentation.

 

    	3

    	 

    

 

d.Survival Regardless
of Investigation. The indemnification and contribution provided for in this Section 1 will remain in full force and effect
regardless of any investigation made by or on behalf of Indemnitee or any officer, director, employee, agent or controlling person
of Indemnitee.

 

e.Change in Control.
The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has been approved
by a majority of the Company’s Board of Directors who were directors immediately prior to such Change in Control) then, with
respect to all matters thereafter arising concerning the rights of Indemnitee to payments of Expenses under this Agreement or any
other agreement or under the Company’s Certificate of Incorporation, as amended (the “Certificate”), or Bylaws
as now or hereafter in effect, Independent Legal Counsel (as defined in Section 10(d) hereof) shall be selected by Indemnitee and
approved by the Company (which approval shall not be unreasonably withheld). Such counsel, among other things, shall render its
written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted to be indemnified
under applicable law. The Company agrees to abide by such opinion and to pay the reasonable fees of the Independent Legal Counsel
referred to above and to fully indemnify such counsel against any and all expenses (including attorneys’ fees), claims, liabilities
and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

f.Mandatory Payment
of Expenses. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful on the
merits or otherwise, including, without limitation, the dismissal of an action without prejudice, in the defense of any action,
suit, proceeding, inquiry or investigation referred to in Section 1(a) hereof or in the defense of any claim, issue or matter therein,
Indemnitee shall be indemnified against all Expenses incurred by Indemnitee in connection herewith.

 

2.Expenses;
Indemnification Procedure.

 

a.Advancement
of Expenses. The Company shall advance all Expenses incurred by Indemnitee. The advances to be made hereunder shall be paid
by the Company to Indemnitee as soon as practicable but in any event no later than fifteen (15) days after written demand by Indemnitee
therefor to the Company.

 

b.Notice/Cooperation
by Indemnitee. Indemnitee shall give the Company notice as soon as practicable of any Claim made against Indemnitee for which
indemnification will or could be sought under this Agreement. Notice to the Company shall be directed to the Chief Executive Officer
of the Company at the address shown on the signature page of this Agreement (or such other address as the Company shall designate
in writing to Indemnitee).

 

c.No Presumptions;
Burden of Proof. For purposes of this Agreement, the termination of any Claim by judgment, order, settlement (whether with
or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption
that Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has determined that
indemnification is not permitted by applicable law. In addition, neither the failure of the Reviewing Party to have made a determination
as to whether Indemnitee has met any particular standard of conduct or had any particular belief, nor an actual determination by
the Reviewing Party that Indemnitee has not met such standard of conduct or did not have such belief, prior to the commencement
of legal proceedings by Indemnitee to secure a judicial determination that Indemnitee should be indemnified under applicable law,
shall be a defense to Indemnitee’s claim or create a presumption that Indemnitee has not met any particular standard of conduct
or did not have any particular belief. In connection with any determination by the Reviewing Party or otherwise as to whether Indemnitee
is entitled to be indemnified hereunder, the burden of proof shall be on the Company to establish that Indemnitee is not so entitled.

 

    	4

    	 

    

 

d.Notice to Insurers.
If, at the time of the receipt by the Company of a notice of a Claim pursuant to Section 2(b) hereof, the Company has liability
insurance in effect which may cover such Claim, the Company shall give prompt written notice of the commencement of such Claim
to the insurers in accordance with the procedures set forth in each of the policies. The Company shall thereafter take all necessary
or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such action, suit,
proceeding, inquiry or investigation in accordance with the terms of such policies.

 

e.Selection of
Counsel. In the event the Company shall be obligated hereunder to pay the Expenses of any Claim, the Company shall be entitled
to assume the defense of such Claim, with counsel reasonably approved by the applicable Indemnitee, upon the delivery to Indemnitee
of written notice of its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention
of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently
incurred by Indemnitee with respect to the same Claim; provided that, (i) Indemnitee shall have the right to employ Indemnitee’s
counsel in any such Claim at Indemnitee’s expense; (ii) Indemnitee shall have the right to employ its own counsel in connection
with any such proceeding, at the expense of the Company, if such counsel serves in a review, observer, advice and counseling capacity
and does not otherwise materially control or participate in the defense of such proceeding; and (iii) if (A) the employment of
counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there
is a conflict of interest between the Company and Indemnitee in the conduct of any such defense, or (C) the Company shall not continue
to retain such counsel to defend such Claim, then the fees and expenses of Indemnitee’s counsel shall be at the expense of
the Company.

 

3.Additional
Indemnification Rights; Nonexclusivity.

 

a.Scope. The
Company hereby agrees to indemnify Indemnitee to the fullest extent permitted by law, even if indemnification is not specifically
authorized by the other provisions of this Agreement or any other agreement, the Certificate, the Company’s Bylaws or by
statute. In the event of any change after the date of this Agreement in any applicable law, statute or rule which expands the right
of a Delaware corporation to indemnify a member of its Board of Directors or an officer, stockholder, employee, controlling person,
agent or fiduciary, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits afforded
by such change. In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware corporation
to indemnify a member of its Board of Directors or an officer, employee, agent or fiduciary, such change, to the extent not otherwise
required by such law, statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the parties’
rights and obligations hereunder except as set forth in Section 8(a) hereof.

 

    	5

    	 

    

 

b.Nonexclusivity.
Notwithstanding anything in this Agreement, the indemnification provided by this Agreement shall be in addition to any rights to
which Indemnitee may be entitled under the Certificate, the Company’s Bylaws, any agreement, any vote of stockholders or
disinterested directors, the laws of the State of Delaware, or otherwise. Notwithstanding anything in this Agreement, the indemnification
provided under this Agreement shall continue as to Indemnitee for any action Indemnitee took or did not take while serving in an
indemnified capacity even though Indemnitee may have ceased to serve in such capacity and indemnification shall inure to the benefit
of Indemnitee from and after Indemnitee’s first day of service as a director with the Company or affiliation with a director
from and after the date such director commences services as a director with the Company.

 

4.No Duplication
of Payments. The Company shall not be liable under this Agreement to make any payment in connection with any Claim made against
any Indemnitee to the extent Indemnitee has otherwise actually received payment (under any insurance policy, Certificate, Bylaws
or otherwise) of the amounts otherwise indemnifiable hereunder.

 

5.Partial Indemnification.
If any Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for any portion of Expenses
incurred in connection with any Claim, but not, however, for all of the total amount thereof, the Company shall nevertheless indemnify
Indemnitee for the portion of such Expenses to which Indemnitee is entitled.

 

6.Mutual Acknowledgement.
The Company and Indemnitee acknowledge that in certain instances, Federal law or applicable public policy may prohibit the Company
from indemnifying its directors, officers, employees, controlling persons, agents or fiduciaries under this Agreement or otherwise.

 

7.Liability
Insurance. During any period of time any Indemnitee is entitled to indemnification rights under this Agreement, the Company
shall maintain liability insurance applicable to directors, officers, employees, control persons, agents or fiduciaries, Indemnitee
shall be covered by such policies in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the
most favorably insured of the Company’s directors, if Indemnitee is a director, or of the Company’s officers, if Indemnitee
is not a director of the Company but is an officer; or of the Company’s key employees, controlling persons, agents or fiduciaries,
if Indemnitee is not an officer or director but is a key employee, agent, control person, or fiduciary. Said liability insurance
shall provide coverage amounts of no less than those specified in Schedule A attached hereto and be held with an insurance carrier
which is the Board of Directors of the Company believes is of financial sound condition.

 

8.Exceptions.
Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement:

 

    	6

    	 

    

 

a.Claims Under
Section 16(b). To indemnify any Indemnitee for expenses and the payment of profits arising from the purchase and sale by Indemnitee
of securities in violation of Section 16(b) of the Exchange Act or any similar successor statute;

 

b.Unlawful Indemnification.
To indemnify Indemnitee if a final decision by a court having jurisdiction in the matter shall determine that indemnification is
not lawful;

 

c.Fraud. To
indemnify Indemnitee if a final decision by a court having jurisdiction in the matter shall determine that Indemnitee has committed
fraud on the Company; or

 

d.Insurance.
To indemnify any Indemnitee for which payment is actually and fully made to Indemnitee under a valid and collectible insurance
policy.

 

9.Period of
Limitations. No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against
any Indemnitee, any Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the expiration
of five (5) years from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished
and deemed released unless asserted by the timely filing of a legal action within such five (5) year period; provided, however,
that if any shorter period of limitations is otherwise applicable to any such cause of action, such shorter period shall govern.

 

10.Construction
of Certain Phrases.

 

a.For purposes of
this Agreement, references to the “Company” shall include, in addition to the resulting corporation, any constituent
corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence
had continued, would have had power and authority to indemnify its directors, officers, employees, agents or fiduciaries, so that
if Indemnitee is or was or may be deemed a director, officer, employee, agent, control person, or fiduciary of such constituent
corporation, or is or was or may be deemed to be serving at the request of such constituent corporation as a director, officer,
employee, control person, agent or fiduciary of another corporation, partnership, joint venture, employee benefit plan, trust or
other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting
or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued.

 

b.For purposes of
this Agreement, references to “other enterprises” shall include employee benefit plans; references to “fines”
shall include any excise taxes assessed on any Indemnitee with respect to an employee benefit plan; and references to “serving
at the request of the Company” shall include any service as a director, officer, employee, agent or fiduciary of the Company
which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee
benefit plan, its participants or its beneficiaries; and if any Indemnitee acted in good faith and in a manner Indemnitee reasonably
believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to
have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

    	7

    	 

    

 

c.For purposes of
this Agreement a “Change in Control” shall be deemed to have occurred if (i) any “person” (as such term
is used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act), other than a trustee or other fiduciary holding securities under
an employee benefit plan of the Company or a corporation owned directly or indirectly by the stockholders of the Company in substantially
the same proportions as their ownership of stock of the Company, (A) who is or becomes the beneficial owner, directly or indirectly,
of securities of the Company representing 20% or more of the combined voting power of the Company’s then outstanding Voting
Securities, increases his beneficial ownership of such securities by 5% or more over the percentage so owned by such person, or
(B) becomes the “beneficial owner” (as defined in Rule 13d-3 under said Exchange Act), directly or indirectly, of securities
of the Company representing more than 30% of the total voting power represented by the Company’s then outstanding Voting
Securities, (ii) during any period of two consecutive years, individuals who at the beginning of such period constitute the Board
of Directors of the Company and any new director whose election by the Board of Directors or nomination for election by the Company’s
stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors
at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to
constitute a majority thereof, or (iii) the stockholders of the Company approve a merger or consolidation of the Company with any
other corporation other than a merger or consolidation which would result in the Voting Securities of the Company outstanding immediately
prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the surviving
entity) at least two-thirds (2/3) of the total voting power represented by the Voting Securities of the Company or such surviving
entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of complete
liquidation of the Company or an agreement for the sale or disposition by the Company of (in one transaction or a series of transactions)
all or substantially all of the Company’s assets.

 

d.For purposes of
this Agreement, “Independent Legal Counsel” shall mean an attorney or firm of attorneys, selected in accordance with
the provisions of Section 1(e) hereof, who shall not have otherwise performed services for the Company or any Indemnitee within
the last three (3) years (other than with respect to matters concerning the right of any Indemnitee under this Agreement, or of
other indemnitees under similar indemnity agreements).

 

e.For purposes of
this Agreement, a “Reviewing Party” shall mean any appropriate person or body consisting of a member or members of
the Company’s Board of Directors or any other person or body appointed by the Board of Directors who is not a party to the
particular Claim for which Indemnitee is seeking indemnification, or Independent Legal Counsel.

 

f.For purposes of
this Agreement, “Voting Securities” shall mean any securities of the Company that vote generally in the election of
directors.

 

11.Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall constitute an original.

 

    	8

    	 

    

 

12.Binding Effect;
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties
hereto and their respective successors, assigns, including any direct or indirect successor by purchase, merger, consolidation
or otherwise to all or substantially all of the business and/or assets of the Company, spouses, heirs, and personal and legal representatives.
The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise)
to all, substantially all, or a substantial part, of the business and/or assets of the Company, by written agreement in form and
substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same
extent that the Company would be required to perform if no such succession had taken place. This Agreement shall continue in effect
with respect to Claims relating to Indemnifiable Events regardless of whether any Indemnitee continues to serve as a director,
officer, employee, agent, controlling person, or fiduciary of the Company or of any other enterprise, including subsidiaries of
the Company, at the Company’s request.

 

13.Attorneys’
Fees. In the event that any action is instituted by Indemnitee under this Agreement or under any liability insurance policies
maintained by the Company to enforce or interpret any of the terms hereof or thereof, any Indemnitee shall be entitled to be paid
all Expenses incurred by Indemnitee with respect to such action if Indemnitee is ultimately successful in such action. In the event
of an action instituted by or in the name of the Company under this Agreement to enforce or interpret any of the terms of this
Agreement, Indemnitee shall be entitled to be paid Expenses incurred by Indemnitee in defense of such action (including costs and
expenses incurred with respect to Indemnitee counterclaims and cross-claims made in such action), and shall be entitled to the
advancement of Expenses with respect to such action, in each case only to the extent that Indemnitee is ultimately successful in
such action.

 

14.Notice.
All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall
in any event be deemed to be given (a) five (5) days after deposit with the U.S. Postal Service or other applicable postal service,
if delivered by first class mail, postage prepaid, (b) upon delivery, if delivered by hand, (c) one business day after the business
day of deposit with Federal Express or similar overnight courier, freight prepaid, or (d) one day after the business day of delivery
by facsimile transmission, if deliverable by facsimile transmission, with copy by first class mail, postage prepaid, and shall
be addressed if to Indemnitee, at Indemnitee’s address as set forth beneath the Indemnitee’s signature to this Agreement
and if to the Company at the address of its principal corporate offices (attention: Secretary) or at such other address as such
party may designate by ten (10) days’ advance written notice to the other party hereto.

 

15.Severability.
The provisions of this Agreement shall be severable in the event that any of the provisions hereof (including any provision within
a single section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable,
and the remaining provisions shall remain enforceable to the fullest extent permitted by law. Furthermore, to the fullest extent
possible, the provisions of this Agreement (including, without limitations, each portion of this Agreement containing any provision
held to be invalid, void or otherwise unenforceable, that is not itself invalid, void or unenforceable) shall be construed so as
to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

    	9

    	 

    

 

16.Choice of
Law. This Agreement shall be governed by and its provisions construed and enforced in accordance with the laws of the State
of Delaware, as applied to contracts between Delaware residents, entered into and to be performed entirely within the State of
Delaware, without regard to the conflict of laws principles thereof.

 

17.Subrogation.
In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights
of recovery of Indemnitee who shall execute all documents required and shall do all acts that may be necessary to secure such rights
and to enable the Company effectively to bring suit to enforce such rights.

 

18.Amendment
and Termination. No amendment, modification, termination or cancellation of this Agreement shall be effective unless it is
in writing signed by the parties to be bound thereby. Notice of same shall be provided to all parties hereto. No waiver of any
of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not
similar) nor shall such waiver constitute a continuing waiver.

 

19.Corporate
Authority. The Board of Directors of the Company and its stockholders in accordance with Delaware law have approved the terms
of this Agreement.

 

(Remainder of page intentionally left
blank)

 

    	10

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Indemnification Agreement on and as of the day and year first above written.

 

	 	APOLLO MEDICAL HOLDINGS, INC.,
	 	a Delaware corporation
	 	 
	 	By: /s/ Mitchell Creem
	 	         Mitchell Creem, Chief Financial Officer
	 	 
	 	 
	 	/s/ Warren Hosseinion 
	 	   Warren Hosseinion, M.D.
	 	 

  

    	S-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]